You are here:

beclometasone dipropionate / formoterol fumarate dihydrate (Fostair)

Advice

following an abbreviated submission

beclometasone dipropionate and formoterol fumarate dihydrate metered dose inhaler 100microgram / 6microgram (Fostair®)  is accepted for use within NHS Scotland.

Indication under review: Symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

Fostair® should be used in patients for whom beclometasone and formoterol are appropriate choices of corticosteroid and long-acting beta2-agonist respectively, and for whom a metered dose inhaler is an appropriate delivery device.

The introduction of Fostair® is likely to be cost neutral. The 100mcg dose of beclometasone in Fostair® is not bioequivalent to a 100mcg dose of beclometasone in several other inhaler formulations.

Drug Details

Drug Name: beclometasone dipropionate / formoterol fumarate dihydrate (Fostair)
SMC Drug ID: 976/14
Manufacturer: Chiesi Limited
Indication: Symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
BNF Category:
Sub Category: 3.2 Corticosteroids
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 7 July 2014

Back